BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) COO Xiaobin Wu sold 500 shares of the firm's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00. Following the completion of the sale, the chief operating officer now owns 4,500 shares of the company's stock, valued at $900,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, September 19th, Xiaobin Wu sold 4,500 shares of BeiGene stock. The stock was sold at an average price of $200.14, for a total value of $900,630.00.
- On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40.
- On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total value of $233,133.61.
BeiGene Price Performance
BGNE opened at $198.59 on Friday. The firm has a market cap of $19.24 billion, a PE ratio of -26.23 and a beta of 0.61. The stock has a 50-day moving average price of $181.25 and a 200-day moving average price of $164.21. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $215.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75.
Kamala’s Dirty Election Move… Revealed
From Paradigm Press | Ad
According to former advisor to the CIA, the Pentagon and the White House Jim Rickards…
Kamala and her puppet masters are planning this dirty election move…
Click here now and learn how to prepare.
BeiGene (NASDAQ:BGNE - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $1.12. The business had revenue of $929.20 million during the quarter, compared to analysts' expectations of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business's revenue for the quarter was up 56.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.64) earnings per share. Sell-side analysts predict that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.
Analysts Set New Price Targets
BGNE has been the subject of several recent research reports. JMP Securities started coverage on BeiGene in a research report on Wednesday. They set a "market outperform" rating and a $288.00 price objective for the company. Bank of America lowered their price target on shares of BeiGene from $180.00 to $152.50 and set a "neutral" rating for the company in a research report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $194.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 20th. Finally, Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $241.21.
Check Out Our Latest Analysis on BGNE
Hedge Funds Weigh In On BeiGene
A number of hedge funds have recently added to or reduced their stakes in the company. Capital International Investors lifted its position in BeiGene by 11.5% during the first quarter. Capital International Investors now owns 7,064,428 shares of the company's stock valued at $1,104,806,000 after purchasing an additional 727,556 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company's stock worth $316,862,000 after buying an additional 117,905 shares during the last quarter. Capital International Inc. CA grew its holdings in shares of BeiGene by 6.0% in the first quarter. Capital International Inc. CA now owns 858,364 shares of the company's stock worth $134,240,000 after acquiring an additional 48,615 shares during the period. Point72 Asset Management L.P. purchased a new stake in BeiGene during the second quarter valued at $54,412,000. Finally, First Trust Advisors LP purchased a new stake in BeiGene during the fourth quarter valued at $39,632,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.
About BeiGene
(
Get Free Report)
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
